Iron metabolism and iron supplementation in cancer patients

Wiener Klinische Wochenschrift

Volumn 127, Issue 23-24, 2015, Pages 907-919

  Ludwig, Heinz ^a   Evstatiev, Rayko ^b   Kornek, Gabriela ^b   Aapro, Matti ^c   Bauernhofer, Thomas ^d   Buxhofer Ausch, Veronika ^e   Fridrik, Michael ^f   Geissler, Dietmar ^g   Geissler, Klaus ^h   Gisslinger, Heinz ^b   Koller, Elisabeth ⁱ   Kopetzky, Gerhard ^j   Lang, Alois ^k   Rumpold, Holger ^l   Steurer, Michael ^d   Kamali, Houman ^m   Link, Hartmut ⁿ  

^a WILHELMINEN HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c CLINIQUE DE GENOLIER   (Switzerland)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e 1 Interne Abt   (Austria)

^f KEPLER UNIVERSITY HOSPITAL   (Austria)

^g GENERAL HOSPITAL KLAGENFURT   (Austria)

^h Krankenhaus Hietzing   (Austria)

ⁱ HANUSCH HOSPITAL   (Austria)

^j Karl Landsteiner Institute for Implementation of Innovative Techniques in Cardiac Surgery   (Austria)

^k Landeskrankenhaus Feldkirch   (Austria)

^l Krankenhaus der Barmherzigen Schwestern Wien Betriebsgesellschaft   (Austria)

^m BRISTOL MYERS SQUIBB   (United States)

ⁿ Westpfalz Klinikum GmbH   (Germany)

more..

Author keywords

Functional and absolute iron deficiency; Iron deficiency; Iron supplementation; Recommendations for clinical practice; Tumor anemia

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; FERROPORTIN; FERROUS ION; HEPCIDIN; IRON; TRANSFERRIN RECEPTOR;

ADVERSE OUTCOME; BLOOD TRANSFUSION; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMORBIDITY; CYTOKINE RELEASE; DIARRHEA; DRUG TOLERABILITY; EPIDEMIOLOGICAL DATA; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON METABOLISM; IRON THERAPY; META ANALYSIS (TOPIC); MONOTHERAPY; NAUSEA; PATHOPHYSIOLOGY; PHYSIOLOGICAL PROCESS; PRACTICE GUIDELINE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT INDICATION; ANEMIA, IRON-DEFICIENCY; AUSTRIA; COMPLICATION; DIETARY SUPPLEMENT; METABOLISM; NEOPLASMS; ONCOLOGY; STANDARDS; TREATMENT OUTCOME;

ANEMIA, IRON-DEFICIENCY; AUSTRIA; DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; HUMANS; IRON; MEDICAL ONCOLOGY; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84951908324     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-015-0842-3     Document Type: Review

References (72)

1. Ponka P. Cellular iron metabolism. Kidney Int. 1999;55:2–11.
2. Ludwig H, Müldür E, Endler G, et al. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol. 2013;24:1886–92.
3. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436–48.
4. Ludwig H, Müldür E, Endler G, et al. High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status. Haematologica. 2011;96(Suppl 2):409.
5. Looker AC, Dallman PR, Carroll MD, et al. Prevalence of iron deficiency in the United States. JAMA. 1997;277:973–6.
6. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40:2293–306.
7. Steurer M, Wagner H, Gastl G. Prevalence and management of anaemia in haematologic cancer patients receiving cyclic nonplatinum chemotherapy: results of a prospective national chart survey. Wien Klin Wochenschr. 2004;116:367–72.
8. Beale AL, Penney MD, Allison MC. The prevalence of iron deficiency among patients presenting with colorectal cancer. Colorectal Dis. 2005;7:398–402.
9. Kuvibidila SR, Gauthier T, Rayford W. Serum ferritin levels and transferrin saturation in men with prostate cancer. J Natl Med Assoc. 2004;96:641–9.
10. Steinmetz HT, Tsamaloukas A, Schmitz S, et al. A new concept for the differential diagnosis and therapy of anaemia in cancer patients. Support Care Cancer. 2010;19:261–9.
11. Beguin Y, Lybaert W, Bosly A. A prospective observational study exploring the impact of iron status on response to darbepoetin alfa in patients with chemotherapy induced anemia. Blood. 2009;114:2007.
12. Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001;91:2214–21.
13. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95:888–95.
14. Hahn A. Physiologische Bedeutung von Eisen. Essenziell und toxisch. Pharm Unserer Zeit. 2009;38:232–9.
15. Evstatiev R, Gasche C. Iron sensing and signalling. Gut. 2012;61:933–52.
16. Hentze MW, Muckenthaler MU, Galy B, et al. Two to tango: regulation of mammalian iron metabolism. Cell. 2010;142:24–38.
17. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood. 2010;116:4754–61.
18. Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46:678–84.
19. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011–23.
20. Grotto HZ. Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Med Oncol. 2008;25:12–21.
21. Tilg H, Ulmer H, Kaser A, et al. Role of IL-10 for induction of anemia during inflammation. J Immunol. 2002;169:2204–9.
22. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1(Suppl 1):4–8.
23. Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica. 2002;87:1209–21.
24. Alkhateeb AA, Connor JR. The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta. 2013;1836:245–54.
25. Aapro M, Osterborg A, Gascon P, et al. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol. 2012;23:1954–62.
26. Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia. 2007;21:627–32.
27. Ludwig H, Endler G, Hübl W, et al. High prevalence of iron deficiency in patients with various hematological and malignant diseases: a single center study in 1989 sequential patients. Haematologica. 2010;95(Suppl 2):702.
28. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010;7:599–610.
29. Verdon F, Burnand B, Stubi CL, et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ. 2003;326:1124.
30. Brownlie Tt, Utermohlen V, Hinton PS, et al. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr. 2004;79:437–43.
31. Bruner AB, Joffe A, Duggan AK, et al. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet. 1996;348:992–6.
32. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 2009;113:3406–17.
33. Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med. 2008;36:2667–74.
34. Thomson A, Farmer S, Hofmann A, et al. Patient blood management—a new paradigm for transfusion medicine? ISBT Science Series. 2009;4:423–35.
35. Rawn J. The silent risks of blood transfusion. Curr Opin Anaesthesiol. 2008;21:664–8.
36. Amato AC, Pescatori M. Effect of perioperative blood transfusions on recurrence of colorectal cancer: meta-analysis stratified on risk factors. Dis Colon Rectum. 1998;41:570–85.
37. Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or darbepoetin for patients with cancer–meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009;(3):CD007303.
38. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001;19:2875–82.
39. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865–74.
40. Ludwig H, Aapro M, Bokemeyer C, et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the anaemia cancer treatment (ACT) study. Eur J Cancer. 2009;45:1603–15.
41. Rizzo JD, Brouwers M, Hurley P, et al. American society of hematology/American society of clinical oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010;116:4045–59.
42. EMA. Summary of Scientific Discussion. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion_-_Variation/human/000332/WC500026146.pdf. Accessed 2015.
43. FDA. Procrit Label, Epogen Label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103234s5199lbl.pdf. Accessed 2015.
44. FDA. Aranesp (darbepoetin alfa) for injection. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103951s5197lbl.pdf. Accessed 2015.
45. NCCN. Cancer- and chemotherapy-induced anemia, Version 2.2014. http://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf (2014). Accessed 2015.
46. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009;69:739–56.
47. Schrijvers D, De Samblanx H, Roila F. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol. 2010;21(Suppl 5):v244–247.
48. Aapro M, Beguin Y, Bokemeyer C, et al. A reappraisal of the ESMO and EORTC guidelines for the management of anaemia and iron deficiency in patients with cancer-related or chemotherapy-induced anaemia. Ann Oncol. 2015.
49. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 2004;22:1301–7.
50. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12:231–42.
51. Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008;26:1611–8.
52. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol. 2008;26:1619–25.
53. Auerbach M, Silberstein PT, Webb RT, et al. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol. 2010;85:655–63.
54. Steensma DP, Sloan JA, Dakhil SR, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol. 2011;29:97–105.
55. Steensma DP, Sasu BJ, Sloan JA, et al. The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial. ASCO Meeting Abstracts. 2011;29:9031.
56. Luporsi E, Mahi L, Morre C, et al. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective. J Med Econ. 2012;15:225–32.
57. Gafter-Gvili A, Rozen-Zvi B, Vidal L, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia—systematic review and meta-analysis of randomised controlled trials. Acta Oncol. 2013;52:18–29.
58. Petrelli F, Borgonovo K, Cabiddu M, et al. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. J Cancer Res Clin Oncol. 2012;138:179–87.
59. Kim YT, Kim SW, Yoon BS, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol. 2007;105:199–204.
60. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol. 2010;116:522–5.
61. Athibovonsuk P, Manchana T, Sirisabya N. Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol Oncol. 2013;131:679–82.
62. Abdel-Razeq H, Abbasi S, Saadi I, et al. Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study. Drug Des Devel Ther. 2013;7:939–44.
63. Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol. 2013;24:475–82.
64. Hedenus M, Karlsson T, Ludwig H, et al. Intravenous ferric carboxymaltose as sole anemia therapy in patients with lymphoid malignancies, chemotherapy-induced anemia and functional iron deficiency Blood. 2013;122:3439.
65. Gilreath JA, Stenehjem DD, Rodgers GM. Total dose iron dextran infusion in cancer patients: is it SaFe2 +. ? J Natl Compr Canc Netw. 2012;10:669–76.
66. Eckard J, Dai J, Wu J, et al. Effects of cellular iron deficiency on the formation of vascular endothelial growth factor and angiogenesis. Iron deficiency and angiogenesis. Cancer Cell Int. 2010;10:28.
67. Beguin Y, Maertens J, De Prijck B, et al. Darbepoetin-alfa and I.V. iron administration after autologous hematopoietic stem cell transplantation: a prospective randomized multicenter trial. Am J Hematol. 2013;88(12):990-6.
68. Aronoff GR, Bennett WM, Blumenthal S, et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int. 2004;66:1193–8.
69. Centre for Evidence Based Medicine (CEBM). Levels of Evidence. http://www.cebm.net/index.aspx?o=1025 (2009). Accessed 2015.
70. KDOQI. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease—CPG and CPR 3.2. Using iron agents. Am J Kidney Dis. 2006;47:58–70.
71. Aapro MS, Beguin Y, Bokemeyer C, et al. Diagnosis, treatment, and use of intravenous iron for chemotherapy-induced anemia in Europe. J Clin Oncol 2011;29:ASCO-Abstract e19557.
72. Kalantar-Zadeh K, McAllister CJ, Regidor DL, et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3070–80.